Late-stage oxidative C(sp3)-H methylation.

Icon for Nature Publishing Group Related Articles

Late-stage oxidative C(sp3)-H methylation.

Nature. 2020 Mar 16;:

Authors: Feng K, Quevedo RE, Kohrt JT, Oderinde MS, Reilly U, White MC

Abstract
Frequently referred to as the 'magic methyl effect', installation of methyl groups, especially adjacent (α) to heteroatoms, has been shown to drastically increase the potency of bioactive molecules1-3. Current methylation methods display limited scope and have not been demonstrated in complex settings1. Here we report a regio- and chemoselective oxidative C(sp3)-H methylation method compatible with late-stage functionalization of drug scaffolds and natural products. This combines a highly site- and chemoselective C-H hydroxylation with a mild, functional-group-tolerant methylation. Using a small-molecule manganese catalyst Mn(CF3PDP) at low loading (substrate/catalyst = 200) afforded targeted C-H hydroxylation on heterocyclic cores, while preserving electron-neutral and electron-rich aryls. Fluorine- or Lewis-acid-assisted formation of reactive iminium or oxonium intermediates enabled the use of a mildly nucleophilic organoaluminum methylating reagent that preserves other electrophilic functionalities on the substrate. The late-stage C(sp3)-H methylation is demonstrated on 41 substrates housing 16 different medicinally important cores that include electron-rich aryls, heterocycles, carbonyls and amines. Eighteen pharmacologically relevant molecules with competing sites-including drugs (for example tedizolid) and natural products-are methylated site-selectively at the most electron rich, least sterically hindered position. Syntheses of two magic methyl substrates, an RORc inverse agonist and an S1P1 antagonist, are demonstrated for the first time via late-stage methylation from the drug or its advanced precursor. Additionally, an unprecedented remote methylation of the B-ring carbocycle of an abiraterone analog is shown. The ability to methylate such complex molecules at late stages will reduce synthetic effort and thereby expedite broader exploration of the magic methyl effect in pursuit of novel small molecule therapeutics and chemical probes.

PMID: 32179876 [PubMed - as supplied by publisher]